Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2024 BOSTON, Feb. 12, 2025 –Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the fourth quarter and full year ended Dec. 31, 2024. "During 2024, we advanced our business in ways that put us much closer to unlocking the value of Amwell and advancing our mission to modernize healthcare with our unified platform," said Ido Schoenberg, MD, ch ...

Core Insights - Amwell announced its financial results for Q4 and the full year ended December 31, 2024, highlighting its position as a leading provider of a comprehensive SaaS-based healthcare platform [1] Company Overview - Amwell is recognized as a leading hybrid care delivery enablement platform in the U.S. and globally, connecting providers, payers, patients, and innovators to enhance access to affordable, high-quality care [3] - The company supports digital health needs across various care types, including urgent, acute, post-acute, chronic care management, and healthy living [3] - Amwell has nearly two decades of experience and powers the digital care of 50 health plans, covering over 80 million lives, and collaborates with many of the largest health systems in the nation [3]

Group 1 - Analysts project that American Well Corporation (AMWL) will report a quarterly loss of $2.82 per share, an increase of 17.1% year over year [1] - Revenues for the upcoming quarter are expected to be $66.57 million, reflecting a decline of 5.8% from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, indicating a reassessment by covering analysts [1] Group 2 - The average prediction for 'Revenue- Platform subscription' is $32.56 million, showing a year-over-year increase of 19.4% [4] - Analysts estimate 'Revenue- Other' will be $8.47 million, indicating a decline of 24.8% year over year [4] - The estimated 'Revenue- Visits' is projected at $25.70 million, reflecting a decrease of 20% from the previous year [4] Group 3 - Over the past month, American Well shares have increased by 33.2%, outperforming the Zacks S&P 500 composite, which rose by 4.2% [5] - Based on its Zacks Rank 3 (Hold), AMWL is expected to perform in line with the overall market in the near future [5]

Company Overview - Amwell is a leading hybrid care delivery enablement platform in the United States and globally, connecting providers, payers, patients, and innovators to enhance access to affordable, high-quality care [3] - The company offers a comprehensive platform that supports various digital health needs, including urgent, acute, post-acute care, chronic care management, and healthy living [3] - Amwell has nearly two decades of experience and powers the digital care of over 50 health plans, representing more than 100 million covered lives, along with many of the largest health systems in the nation [3] Upcoming Earnings Report - Amwell will report its fourth quarter 2024 operating results after stock market trading hours on February 12, 2025 [1] - Following the earnings alert, the management team will host a live conference call and webcast at 5 p.m. ET to review the operating results and provide a general business update [1][2] - The full earnings report and the live audio webcast can be accessed through the Investors section of the company's website, with a replay available for approximately 90 days [2]

Partnership Overview - Vida Health partners with Amwell to provide personalized, high-touch care, aiming to reduce member friction, improve health outcomes, and lower costs [1] - The collaboration integrates Vida's cardiometabolic care solutions, including GLP-1s and anti-obesity medications, into Amwell's platform [7][9] Program Details - The program, Amwell Cardiometabolic Care Powered by Vida, offers a suite of services including obesity, diabetes prevention, management, and behavioral health support [5] - Care is tailored based on social factors such as food security, financial barriers, cultural norms, and beliefs [5] - Vida's services are available alongside Amwell's existing virtual primary care, urgent care, and behavioral health programs [5] Industry Context - Over 40% of American adults struggle with obesity, which increases the risk of diabetes, heart disease, and cancer [1] - Obesity and diabetes collectively cost the U S healthcare system more than $500 billion annually [1] Company Profiles - Amwell is a leading hybrid care delivery platform, connecting providers, payers, patients, and innovators to deliver affordable, high-quality care [6] - Amwell powers digital care for over 50 health plans, representing more than 100 million covered lives [6] - Vida Health is a virtual obesity and metabolic care provider, offering personalized care with a holistic approach combining human care and AI-powered insights [8] - Vida operates on a value-based pricing model, focusing on measurable outcomes and serving members in all 50 states [8] Strategic Impact - The partnership allows Amwell's health plan clients to offer members a single entry point for clinical and behavioral health support related to obesity and related illnesses [9] - Vida's programs adapt to patient needs, providing a personalized, cost-effective approach to weight loss and chronic disease management [9] - Amwell's clinical programs portfolio features virtual and digital care products from partners, offering a unified and comprehensive care model [9]

Company Performance and Financials - American Well is expected to post a quarterly loss of $2 82 per share in its upcoming report representing a year-over-year change of +17 1% [2] - Revenues are expected to be $66 57 million down 5 8% from the year-ago quarter [2] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days [3] - American Well Corporation (AMWL) shares rallied 18 8% in the last trading session to close at $8 58 [5] Industry and Peer Comparison - American Well is part of the Zacks Medical Info Systems industry [3] - Standard BioTools (LAB) another stock in the same industry closed the last trading session 26 4% higher at $2 06 [3] - LAB has returned -14 7% in the past month [3] - For Standard BioTools the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0 03 representing a change of +62 5% from what the company reported a year ago [4] Strategic Transactions - American Well sold its Amwell Psychiatric Care (APC) business to Avel eCare for approximately $21M in cash at closing and an additional earn-out payment [1] - The transaction will strengthen American Well's balance sheet while emphasizing the focus on growing accretive software contribution in the product mix [1]

Divestment of Amwell Psychiatric Care intended to focus product portfolio on key growth initiatives Company reiterates guidance for 2024 BOSTON, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a global leader in digital care, today announced it has sold its Amwell Psychiatric Care (APC) business to Avel eCare, a national leading provider of clinician-to-clinician telehealth services. With the divestiture of APC, a virtual psychiatric care service that Amwell purchased in 2019, Amwell continues to s ...

Core Insights - Amwell has announced that CFO Mark Hirschhorn will take on an expanded role as Chief Operating Officer effective January 1, 2025, reflecting the company's commitment to scaling its digital healthcare solutions [1][2] - Hirschhorn will oversee operational and growth strategies, including clinical, sales, and marketing teams, while maintaining his CFO responsibilities [2][3] - The company aims to achieve cash flow positivity by 2026, emphasizing a focus on operational efficiency and profitable growth [3] Leadership Changes - Two executives, Chief Commercial and Growth Officer Kathy Weiler and Chief Operating Officer Kurt Knight, will depart Amwell at the end of the year [2][4] - Weiler has significantly contributed to cost initiatives and the transformation of the growth organization, while Knight has played a key role in strategy, M&A, and scaling operations during the COVID-19 pandemic [2][4] Company Overview - Amwell is a leading hybrid care delivery platform in the U.S. and globally, connecting providers, payers, patients, and innovators to enhance access to affordable, high-quality care [5] - The company supports digital health needs across various care types, including urgent, acute, post-acute, chronic care management, and healthy living [5] - Amwell serves over 50 health plans, representing more than 100 million covered lives, and collaborates with many of the largest health systems in the nation [5]

American Well Corporation (NYSE:AMWL) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Sue Dooley - Head of Investor Relations Ido Schoenberg - Chairman and Chief Executive Officer Mark Hirschhorn - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Ryan MacDonald - Needham & Company Stan Berenshteyn - Wells Fargo Jailendra Singh - Truist Securities Charles Rhyee - TD Cowen Dave Larsen - BTIG Operator Ladies and gentlemen, good afternoon. ...

Core Insights - American Well Corporation (AMWL) reported revenue of $61.05 million for the quarter ended September 2024, a decrease of 1.4% year-over-year [1] - The company's EPS was -$2.87, an improvement from -$4.00 in the same quarter last year [1] - Revenue fell short of the Zacks Consensus Estimate of $62.06 million, resulting in a surprise of -1.64%, while the EPS exceeded expectations by 13.55% [1] Revenue Breakdown - Platform subscription revenue was $26.23 million, below the estimated $27.23 million, reflecting a year-over-year decline of 7.6% [3] - Other revenue reached $7.35 million, surpassing the average estimate of $6.13 million, marking a year-over-year increase of 7.4% [3] - Revenue from visits was $27.47 million, compared to the average estimate of $28.60 million, indicating a year-over-year growth of 2.8% [3] Stock Performance - Over the past month, American Well's shares have returned +4.2%, outperforming the Zacks S&P 500 composite's +1.8% change [4] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [4]